AnodyneWiki

Sibutramine

Sibutramine
Sibutramine
Salts
[]
Sibutramine hydrochloride
Sibutramine hydrochloride
Sibutramine mesylate
Sibutramine mesylate
Sibutramine maleate
Sibutramine maleate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass279.80 g/mol [1]
Melting point191-192 °C [1]
DecompositionWhen heated to decomposition, material emits very toxic fumes of /hydrogen chloride/ and /nitrogen oxides/. Emits toxic fumes [1]
Solubility2.9 mg/mL (in pH 5.2 water) [1]
Predicted LogP5.4 [1]
Structural Identifiers
[]
Molecular formulaC17H26ClN
IUPAC name1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
SMILESCC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
InChIInChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
InChIKeyUNAANXDKBXWMLN-UHFFFAOYSA-N
CAS number106650-56-0
UNIIWV5EC51866
PubChem CID5210
Pharmacokinetics[]
Elimination half-life1 hour (sibutramine), 14 hours (M<sub>1</sub>) & 16 hours (M<sub>2</sub>)
MetabolismHepatic (CYP3A4-mediated)
ExcretionUrine (77%), feces (8%)
Routes of administrationBy mouth
Dependence liabilityPhysical: Low Psychological: Very High

Sibutramine (also known as Medaria, Sibutraminum, Butramin, Sibutramina, racemic sibutramine, Cf-alli, 1-(1-(4-chlorophenyl)cyclobutyl)-N,N,3-trimethylbutan-1-amine, Hsdb 7209, N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine or Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-) is a stimulant substance of the amphetamine class.

Chemistry

Salts []

Sibutramine is typically found in the form of its hydrochloride, mesylate and maleate salts.

 []

Sibutramine is a racemic mixture of the (optical activity ( + / - )).

Stereoisomers from PubChem

Sibutramine matches Lipinski's rule of five (violations: 1).

There are currently 3 reagent-interactions on

ReagentColor changeDescription
Marquisno color change
Meckeno color change
Mandelinno color change

Pharmacology

Mechanism of action []

Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target1

Medical side effects []

338 side effects listed on drug labels in (sibutramine).

  • Anaphylactic shock
  • Anaphylactoid reaction
  • Angioedema
  • Hypersensitivity
  • Completed suicide
  • Urticaria
  • Rash
  • Suicidal ideation
  • Abdominal pain
  • Gastrointestinal pain
  • Abscess
  • Albuminuria
  • Alopecia
  • Amblyopia
  • Amenorrhoea
  • Amnesia
  • Short-term memory loss
  • Anaemia
  • Anger
  • Angina pectoris
  • Decreased appetite
  • Anxiety
  • Apnoea
  • Arrhythmia
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Arthritis
  • Rheumatoid arthritis
  • Asthenia
  • Asthma
  • Ataxia
  • Atrial fibrillation
  • Back pain
  • Blister
  • Dermatitis bullous
  • Bone disorder
  • Brain neoplasm
  • Bronchitis
  • Bundle branch block
  • Bursitis
  • Neoplasm malignant
  • Cardiovascular disorder
  • Cellulitis
  • Transient ischaemic attack
  • Neck pain
  • Cheilitis
  • Chest pain
  • Retrosternal pain
  • Cholecystitis
  • Cholelithiasis
  • Colitis
  • Infection
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Conjunctivitis
  • Constipation
  • Contusion
  • Cough
  • Cough increased
  • Cystitis
  • Bladder pain
  • Cystitis noninfective
  • Libido decreased
  • Disturbance in sexual arousal
  • Libido increased
  • Dysphagia
  • Dehydration
  • Delusion
  • Dental caries
  • Depression
  • Depression aggravated
  • Dermatitis
  • Dermatitis contact
  • Diabetes mellitus
  • Diarrhoea
  • Dizziness
  • Syncope
  • Duodenal ulcer
  • Dysgeusia
  • Dysmenorrhoea
  • Dyspepsia
  • Dyspnoea
  • Dysuria
  • Ear disorder
  • Ear pain
  • Ecchymosis
  • Eczema
  • Oedema
  • Enteritis
  • Eosinophilia
  • Epididymitis
  • Epilepsy
  • Epistaxis
  • Eructation
  • Oesophagitis
  • Eye disorder
  • VIIth nerve paralysis
  • Hepatic steatosis
  • Body temperature increased
  • Flatulence
  • Furuncle
  • Gastritis
  • Gastroenteritis
  • Gastrointestinal disorder
  • Gastrointestinal haemorrhage
  • Gingivitis
  • Glaucoma
  • Glomerulonephritis membranoproliferative
  • Glossitis
  • Goitre
  • Gout
  • Hair disorder
  • Breath odour
  • Headache
  • Cardiac arrest
  • Cardiac failure congestive
  • Haematuria
  • Haemorrhage
  • Haemoglobin
  • Haemorrhoids
  • Hernia
  • Herpes simplex
  • Herpes zoster
  • Hostility
  • Hyperbilirubinaemia
  • Hypercholesterolaemia
  • Hyperglycaemia
  • Hyperkalaemia
  • Hyperlipidaemia
  • Hypertension
  • Malignant hypertension
  • Hyperthyroidism
  • Hyperventilation
  • Hypoaesthesia
  • Hypoglycaemia
  • Hypokalaemia
  • Hypotension
  • Orthostatic hypotension
  • Hypothyroidism
  • Immune system disorder
  • Inflammation
  • Influenza
  • Intestinal obstruction
  • Iritis
  • Arthropathy
  • Osteoarthritis
  • Lacrimal disorder
  • Lacrimal structural disorder
  • Laryngitis
  • Muscle spasms
  • Leukocytosis
  • Leukopenia
  • Lung disorder
  • Lymphocytosis
  • Menstrual disorder
  • Metrorrhagia
  • Hypertonia
  • Myopathy
  • Myocardial infarction
  • Acute coronary syndrome
  • Myoclonus
  • Nail disorder
  • Nasal congestion
  • Nausea
  • Neoplasm
  • Tubulointerstitial nephritis
  • Acute interstitial nephritis
  • Nervousness
  • Tension
  • Neuralgia
  • Neuritis
  • Neuropathy peripheral
  • Neurosis
  • Nightmare
  • Osteoporosis
  • Otitis externa
  • Otitis media
  • Pain
  • Pain in extremity
  • Palpitations
  • Paraesthesia
  • Pelvic pain
  • Tooth abscess
  • Personality disorder
  • Petechiae
  • Pharyngitis
  • Phlebitis
  • Pneumonia
  • Supraventricular extrasystoles
  • Pruritus
  • Psoriasis
  • Psychotic disorder
  • Psychotic episode
  • Purpura
  • Vascular purpura
  • Henoch-Schonlein purpura
  • Anorectal disorder
  • Retinal disorder
  • Rhinitis
  • Convulsion
  • Sepsis
  • Shock
  • Salivary hypersecretion
  • Sinusitis
  • Skin disorder
  • Neoplasm skin
  • Skin mass
  • Skin ulcer
  • Speech disorder
  • Gastric ulcer
  • Stomatitis
  • Mouth ulceration
  • Cerebrovascular accident
  • Hyperhidrosis
  • Loss of consciousness
  • Tachycardia
  • Supraventricular tachycardia
  • Tenosynovitis
  • Thirst
  • Thrombocytopenia
  • Thyroid disorder
  • Tinnitus
  • Tongue disorder
  • Tongue oedema
  • Tooth disorder
  • Torsade de pointes
  • Torticollis
  • Tourette's disorder
  • Tremor
  • Pollakiuria
  • Urinary incontinence
  • Urinary tract infection
  • Varicose vein
  • Angiopathy
  • Vascular headache
  • Vasodilation procedure
  • Ventricular fibrillation
  • Ventricular tachycardia
  • Vertigo
  • Vestibular disorder
  • Vomiting
  • Weight increased
  • Dry mouth
  • Yawning
  • Urinary retention
  • Peripheral vascular disorder
  • Chills
  • Agitation
  • Hyperkinesia
  • Apathy
  • Flat affect
  • Mood swings
  • Affect lability
  • Rash pustular
  • Oedema peripheral
  • Monocytosis
  • Cataract
  • Hepatic function abnormal
  • Migraine
  • Alcohol intolerance
  • Hormone level abnormal
  • Blood urea increased
  • Blood creatinine increased
  • Generalised oedema
  • Fluid retention
  • Ventricular extrasystoles
  • Gamma-glutamyltransferase increased
  • Skin hypertrophy
  • Injury
  • Liver function test abnormal
  • Mania
  • Bone pain
  • Eye pain
  • Paraesthesia oral
  • Blood alkaline phosphatase increased
  • Aspartate aminotransferase increased
  • Alanine aminotransferase increased
  • Dry skin
  • Abnormal faeces
  • Iron deficiency anaemia
  • Malnutrition
  • Hangover
  • Rash macular
  • Rash vesicular
  • Discomfort
  • Ill-defined disorder
  • Muscle twitching
  • Chest discomfort
  • Chest pressure
  • Increased appetite
  • Thinking abnormal
  • Mental disability
  • Cerebration impaired
  • Abnormal dreams
  • Intraocular pressure increased
  • Euphoric mood
  • Disturbance in attention
  • Therapeutic response unexpected
  • Erectile dysfunction
  • Rectal haemorrhage
  • Nephritis
  • Nephritic syndrome
  • Major depression
  • Dry eye
  • Vision blurred
  • Photosensitivity reaction
  • Abdominal distension
  • Akathisia
  • Bradycardia
  • Laboratory test abnormal
  • Lymphadenopathy
  • Blood pressure increased
  • Sudden death
  • Vasculitic rash
  • Electrocardiogram abnormal
  • Face oedema
  • Gait disturbance
  • Serotonin syndrome
  • Acne
  • Blood uric acid increased
  • Hyperuricaemia
  • Hallucinations, mixed
  • Thrombocytosis
  • Sleep disorder
  • Cerebral ischaemia
  • Insomnia
  • Muscular weakness
  • Parosmia
  • Renal failure
  • Renal impairment
  • Breast enlargement
  • Somnolence
  • Ejaculation disorder
  • Right ventricular failure
  • Vaginal haemorrhage
  • Visual impairment

Indications

  • Increased activity
  • Obesity
  • Weight decreased

Subjective effects []

Experience reports

Erowid

There are currently 1 experience reports involving sibutramine on : []

 []

  • Australia: Sibutramine is a Schedule 9.
  • Brazil: Sibutramine is a B2.[3]
  • United States: Sibutramine is a Schedule IV under the "Controlled Substances Act".

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5210, Sibutramine. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5210
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Sibutramine. UNII: WV5EC51866. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WV5EC51866
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 10:00:48
drugsprook2026-11-20 10:00:44
erowidok2026-11-20 10:00:49
gsrsok2026-11-20 10:00:48
hmdbmissing (hmdb.ca refused automated access to HMDB0015237)2026-11-20 10:00:44
keggok2026-11-20 10:00:46
pubchemok2026-11-20 10:00:42
redditmissing (no r/tripreports posts mention it)2026-11-20 10:00:44
siderok2026-11-20 10:00:44
structureok2026-11-20 10:00:44
wikipediaok2026-11-20 10:00:45